keyword
MENU ▼
Read by QxMD icon Read
search

gist cancer

keyword
https://www.readbyqxmd.com/read/29237949/diagnosis-and-management-of-gastrointestinal-stromal-tumors-an-up-to-date-literature-review
#1
REVIEW
Ayman El-Menyar, Ahammed Mekkodathil, Hassan Al-Thani
Gastrointestinal stromal tumors (GISTs) are rare life-threatening forms of cancer that may arise anywhere in the GI tract. Herein, we aimed to review the literature to describe the incidence, management, and outcomes of GISTs. We conducted a traditional narrative review using PubMed and EMBASE, searching for English-language publications for GISTs between January 2001 and January 2016 using keywords "gastrointestinal" "stromal tumors." Among 4582 retrieved articles, 50 articles were relevant over the last 15 years...
October 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/29234186/primary-leiomyosarcoma-of-the-mesentery-a-case-report
#2
Varsha Dalal, Manveen Kaur, Reetika Menia, Fouzia Siraj, Amar Bhatnagar, Usha Agrawal
Mesenteric masses are infrequent lesions ranging from benign cysts to aggressive malignancies and often present a diagnostic and therapeutic challenge. The mesentery is a frequent recipient of metastases from the gastrointestinal tract, pancreas, and biliary cancers. Primary mesenteric tumors are relatively rare, mostly mesenchymal in origin and benign in nature. Examples include gastrointestinal stromal tumors and smooth muscle tumors. We describe a 50-year-old woman, who presented with a lump in the left hypochondrium along with altered bowel habits of 2 years' duration...
September 2017: Iranian Journal of Medical Sciences
https://www.readbyqxmd.com/read/29232272/relative-effects-of-age-race-and-stage-on-mortality-in-gestational-choriocarcinoma
#3
Christopher M Tarney, Chunqiao Tian, Eric R Craig, Barbara A Crothers, John K Chan, Glenn D Gist, Nicholas W Bateman, Thomas P Conrads, Chad A Hamilton, George Larry Maxwell, Kathleen M Darcy
OBJECTIVE: Gestational choriocarcinoma is a malignant form of gestational trophoblastic disease that usually arises after a molar pregnancy, but may follow any antecedent pregnancy. Investigations in this rare cancer are limited. We evaluated the prognostic effects of age, race, and stage in choriocarcinomas diagnosed for 4 decades. METHODS: Patients diagnosed as having gestational choriocarcinoma between 1973 and 2014 from the Surveillance, Epidemiology, and End Results program were eligible...
December 11, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29220298/gastrointestinal-stromal-tumors
#4
Margaret von Mehren, Heikki Joensuu
GI stromal tumors (GISTs) are neoplasms with a varying malignancy potential ranging from virtually indolent tumors to rapidly progressing cancers. GISTs occur throughout the intestinal tract, and most harbor an activating mutation in either KIT or platelet-derived growth factor A ( PDGFRA). Diagnosis is made using immunohistochemistry, but molecular testing with mutation analysis is paramount for selection of appropriate therapy. Most small GISTs are cured with surgery. Tyrosine kinase inhibitor (TKI) therapy has led to substantial improvements in survival, both for patients with localized GIST and those with advanced disease...
December 8, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29207963/two-staging-systems-for-gastrointestinal-stromal-tumors-in-the-stomach-which-is-better
#5
Chul Hong Park, Gwang Ha Kim, Bong Eun Lee, Geun Am Song, Do Youn Park, Kyung Un Choi, Dae Hwan Kim, Tae Yong Jeon
BACKGROUND: The prognosis of a gastrointestinal stromal tumor (GIST) is influenced by its anatomic site; however, few studies on the prognosis of gastric GISTs have been reported. The aims of this study were to evaluate long-term prognoses of patients who underwent surgical resection for gastric GISTs and to compare the clinical efficacy of two staging systems: the National Institutes of Health (NIH) consensus criteria and the 7th Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) tumor-node-metastasis (TNM) staging system...
December 6, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/29167690/synchronous-gists-associated-with-multiple-sporadic-tumors-a-case-report
#6
Danila Comandini, Azzurra Damiani, Alessandro Pastorino
Gastrointestinal stromal tumors (GISTs) are rare neoplasms, but they also represent the most common mesenchymal tumors of the gastrointestinal tract originating from the cell of Cajal. GIST incidence ranges around 1% of all gastrointestinal malignancies. Approximately 5% of all GISTs have a hereditary etiology. The remaining 95% of GISTs are considered sporadic events, with up to 75% of cases driven by a constitutional activation of the c-KIT proto-oncogene. GISTs are generally solitary lesions. Nonetheless, multiple sporadic GISTs can occur and present as synchronous or metachronous tumors, usually associated with familial GIST...
2017: Drugs in Context
https://www.readbyqxmd.com/read/29162563/foxf1-defines-the-core-regulatory-circuitry-in-gastrointestinal-stromal-tumor-gist
#7
Leili Ran, Yuedan Chen, Jessica Sher, Wai Pung E Wong, Devan Murphy, Jenny Q Zhang, Dan Li, Kemal Deniz, Inna Sirota, Zhen Cao, Shangqian Wang, Youxin Guan, Shipra Shukla, Katie Yang Li, Alan Chramiec, Yuanyuan Xie, Deyou Zheng, Richard P Koche, Cristina R Antonescu, Yu Chen, Ping Chi
The cellular context that integrates upstream signaling and downstream nuclear response dictates the oncogenic behaviour and shapes treatment responses in distinct cancer types. Here, we uncover that in GIST, the forkhead family member, FOXF1, directly controls the transcription of two master regulators, KIT and ETV1, both required for GIST precursor-interstitial cells of Cajal (ICC) lineage-specification and GIST tumorigenesis. Further, FOXF1 co-localizes with ETV1 at enhancers and functions as a pioneer factor that regulates the ETV1-dependent GIST-lineage specific transcriptome through modulation of the local chromatin context, including chromatin accessibility, enhancer maintenance and ETV1 binding...
November 21, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/29145813/impact-of-a-decision-aid-about-stratified-ovarian-cancer-risk-management-on-women-s-knowledge-and-intentions-a-randomised-online-experimental-survey-study
#8
Susanne F Meisel, Maddie Freeman, Jo Waller, Lindsay Fraser, Sue Gessler, Ian Jacobs, Jatinderpal Kalsi, Ranjit Manchanda, Belinda Rahman, Lucy Side, Jane Wardle, Anne Lanceley, Saskia C Sanderson
BACKGROUND: Risk stratification using genetic and other types of personal information could improve current best available approaches to ovarian cancer risk reduction, improving identification of women at increased risk of ovarian cancer and reducing unnecessary interventions for women at lower risk. Amounts of information given to women may influence key informed decision-related outcomes, e.g. knowledge. The primary aim of this study was to compare informed decision-related outcomes between women given one of two versions (gist vs...
November 16, 2017: BMC Public Health
https://www.readbyqxmd.com/read/29145240/gastrointestinal-stromal-tumor-gist-with-liver-metastases-an-18-year-experience-from-the-gist-cooperation-group-in-north-china
#9
MULTICENTER STUDY
Yi-Nan Shi, Yong Li, Li-Ping Wang, Zhen-Hua Wang, Xiao-Bo Liang, Han Liang, Li Zhang, Bin Li, Li-Qiao Fan, Qun Zhao, Zhi-Xue Ma, Xue-Feng Zhao, Zhi-Dong Zhang, Yu Liu, Bi-Bo Tan, Dong Wang, Li-Li Wang, Ying-Jie Hao, Nan Jia
Approximately 40% to 50% of gastrointestinal stromal tumor (GIST) patients will have recurrence or metastases after resection of the primary lesion, and the most common affected sites will be liver and peritoneum. Imatinib has been considered as the first-line therapy of metastatic GIST. Surgery for metastases is proposed when possible. Furthermore, there are controversies concerning hepatic resection and systemic tyrosin kinase inhibitors (TKIs). The therapeutic conditions and long-term outcome of GIST patients with liver metastases in northern China remain unknown...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29115925/synchronous-occurrence-of-hereditary-gastric-adenocarcinoma-gastrointestinal-stromal-tumor-and-esophageal-small-cell-and-squamous-carcinoma-in-situ-an-extremely-rare-case-report
#10
Huijie Fan, Pei Lu, Li Xu, Yanru Qin, Jing Li
BACKGROUND: Hereditary diffuse gastric carcinoma (HDGC) accounts for 1-3% of all gastric carcinomas. Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the gastrointestinal (GI) tract but they comprise fewer than 1% of all GI malignancies. Small-cell carcinoma (SmCC) is a rare histological type of esophageal carcinoma, accounting for 0.4% to 2.8% of all esophageal tumors. Co-occurrence of SmCC with esophageal tumors caused by squamous carcinoma is also very uncommon...
November 7, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29113198/downregulation-of-mir-186-is-associated-with-metastatic-recurrence-of-gastrointestinal-stromal-tumors
#11
Takeshi Niinuma, Masahiro Kai, Hiroshi Kitajima, Eiichiro Yamamoto, Taku Harada, Reo Maruyama, Takayuki Nobuoka, Toshirou Nishida, Tatsuo Kanda, Tadashi Hasegawa, Takashi Tokino, Tamotsu Sugai, Yasuhisa Shinomura, Hiroshi Nakase, Hiromu Suzuki
Although dysregulation of microRNAs (miRNAs/miRs) is a common feature of human malignancies, its involvement in gastrointestinal stromal tumors (GISTs) is not fully understood. The present study aimed to identify the miRNAs that perform a role in GIST metastasis. miRNA expression profiles from a series of 32 primary GISTs were analyzed using microarrays, and miR-186 was observed to be downregulated in tumors exhibiting metastatic recurrence. Reverse transcription-quantitative polymerase chain reaction analysis of an independent cohort of 100 primary GISTs revealed that low miR-186 expression is associated with metastatic recurrence and a poor prognosis...
November 2017: Oncology Letters
https://www.readbyqxmd.com/read/29113157/lack-of-microsatellite-instability-in-gastrointestinal-stromal-tumors
#12
Nathália C Campanella, Cristovam Scapulatempo-Neto, Lucas Faria Abrahão-Machado, Antônio Talvane Torres De Oliveira, Gustavo N Berardinelli, Denise Peixoto Guimarães, Rui M Reis
The microsatellite instability (MSI) phenotype may constitute an important biomarker for patient response to immunotherapy, particularly to anti-programmed death-1 inhibitors. MSI is a type of genomic instability caused by a defect in DNA mismatch repair (MMR) proteins, which is present mainly in colorectal cancer and its hereditary form, hereditary nonpolyposis colorectal cancer. Gastrointestinal stromal tumor (GIST) development is associated with activating mutations of KIT proto-oncogene receptor tyrosine kinase (KIT) or platelet-derived growth factor receptor α (PDGFRA), which are oncogenes that predict the response to imatinib mesylate...
November 2017: Oncology Letters
https://www.readbyqxmd.com/read/29107068/targeting-tumor-cells-based-on-phosphodiesterase-3a-expression
#13
Madiha Nazir, Wojciech Senkowski, Frida Nyberg, Kristin Blom, Per-Henrik Edqvist, Malin Jarvius, Claes Andersson, Mats G Gustafsson, Peter Nygren, Rolf Larsson, Mårten Fryknäs
We and others have previously reported a correlation between high phosphodiesterase 3A (PDE3A) expression and selective sensitivity to phosphodiesterase (PDE) inhibitors. This indicates that PDE3A could serve both as a drug target and a biomarker of sensitivity to PDE3 inhibition. In this report, we explored publicly available mRNA gene expression data to identify cell lines with different PDE3A expression. Cell lines with high PDE3A expression showed marked in vitro sensitivity to PDE inhibitors zardaverine and quazinone, when compared with those having low PDE3A expression...
October 26, 2017: Experimental Cell Research
https://www.readbyqxmd.com/read/29100729/musings-on-social-media-and-gist-gastrointestinal-stromal-cancer
#14
EDITORIAL
Richard J Shader
No abstract text is available yet for this article.
October 31, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29093181/a-precision-therapy-against-cancers-driven-by-kit-pdgfra-mutations
#15
Erica K Evans, Alexandra K Gardino, Joseph L Kim, Brian L Hodous, Adam Shutes, Alison Davis, Xing Julia Zhu, Oleg Schmidt-Kittler, Doug Wilson, Kevin Wilson, Lucian DiPietro, Yulian Zhang, Natasja Brooijmans, Timothy P LaBranche, Agnieszka Wozniak, Yemarshet K Gebreyohannes, Patrick Schöffski, Michael C Heinrich, Daniel J DeAngelo, Stephen Miller, Beni Wolf, Nancy Kohl, Timothy Guzi, Nicholas Lydon, Andy Boral, Christoph Lengauer
Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that heterogeneous mutations within a single kinase can result in various mechanisms of kinase activation. Therapeutic benefit to patients can best be optimized through an in-depth understanding of the disease-driving mutations combined with the ability to match these insights to tailored highly selective drugs...
November 1, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/29074353/clinical-features-of-regorafenib-induced-liver-injury-in-japanese-patients-from-postmarketing-experience
#16
Hiroyuki Uetake, Kenichi Sugihara, Kei Muro, Toshiyuki Sunaya, Yuka Horiuchi-Yamamoto, Hajime Takikawa
BACKGROUND: Regorafenib (Stivarga) is an oral multikinase inhibitor currently approved for patients with metastatic colorectal cancer or gastrointestinal stromal tumor. Although hepatotoxicity has been a known product profile feature of regorafenib since its initial approval, its clinical features are limited to those found in the clinical trials. PATIENTS AND METHODS: The present study was conducted in 2 analysis sets: a safety analysis set for metastatic colorectal cancer from solicited postmarketing surveillance (PMS) in Japan (n = 1227) and an analysis set for serious hepatic adverse drug reactions (n = 210) from all patients registered for regorafenib use...
September 28, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29028887/identification-of-cancer-driver-genes-in-focal-genomic-aberrations-from-whole-exome-sequencing-data
#17
Ho Jang, Hyunju Lee
Summary: Whole-exome sequencing (WES) data have been used for identifying copy number aberrations in cancer cells. Nonetheless, the use of WES is still challenging for identification of focal aberrant regions in multiple samples that may contain cancer driver genes. In this study, we developed a wavelet-based method for identifying focal genomic aberrant regions in the WES data from cancer cells (WIFA-X). When we applied WIFA-X to glioblastoma multiforme and lung adenocarcinoma datasets, WIFA-X outperformed other approaches on identifying cancer driver genes...
September 28, 2017: Bioinformatics
https://www.readbyqxmd.com/read/28991465/inhibitors-to-overcome-secondary-mutations-in-the-stem-cell-factor-receptor-kit
#18
Helena Kaitsiotou, Marina Keul, Julia Hardick, Thomas Mühlenberg, Julia Ketzer, Christiane Ehrt, Jasmin Krüll, Federico Medda, Oliver Koch, Fabrizio Giordanetto, Sebastian Bauer, Daniel Rauh
In modern cancer therapy, the use of small organic molecules against receptor tyrosine kinases (RTKs) has been shown to be a valuable strategy. The association of cancer cells with dysregulated signaling pathways linked to RTKs represents a key element in targeted cancer therapies. The tyrosine kinase mast/stem cell growth factor receptor KIT is an example of a clinically relevant RTK. KIT is targeted for cancer therapy in gastrointestinal stromal tumors (GISTs) and chronic myelogenous leukemia (CML). However, acquired resistance mutations within the catalytic domain decrease the efficacy of this strategy and are the most common cause of failed therapy...
October 24, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28990511/sunitinib-in-the-treatment-of-thyroid-cancer
#19
Ferrari Silvia Martinaa, Centanni Marco, Virili Camilla, Miccoli Mario, Ferrari Paola, Ruffilli Ilaria, Ragusa Francesca, Antonelli Alessandro, Fallahi Poupak
BACKGROUND: Sunitinib (SU11248) is an oral, small-molecule, multi-targeted tyrosine kinase inhibitor (TKI), that inhibits receptors for platelet-derived growth factor (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs), c-KIT, fms-related tyrosine kinase 3 (FLT3) and RET. The concurrent inhibition of these pathways reduces tumor vascularization and causes cancer cell apoptosis, inducing a tumor shrinkage. Sunitinib is approved for the treatment of imatinib-resistant gastrointestinal stromal tumor (GIST), renal carcinoma, and pancreatic neuroendocrine tumors...
October 6, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28988888/small-bowel-tumors-a-digestive-endoscopy-society-of-taiwan-dest-multicenter-enteroscopy-based-epidemiologic-study
#20
Chen-Shuan Chung, Chi-Ming Tai, Tien-Yu Huang, Chen-Wang Chang, Kuan-Chih Chen, Chao-Ming Tseng, Horng-Yuan Wang, Cheng-Hsin Chu, Jiann-Ming Wu, Yun Chen, Hsiu-Po Wang
BACKGROUND/PURPOSE: Small bowel (SB) accounts for the majority of gastrointestinal tract but its tumors are rare and always overlooked. In this study, we aimed to evaluate the epidemiology of SB tumors. METHODS: This multicenter retrospective study utilized endoscopy database from 2006/11 to 2016/07. Baseline demographic characteristics, clinical, radiologic and endoscopic findings were collected. RESULTS: Totally 103 (34 benign, 69 malignant lesions) patients with SB tumors in 1070 enteroscopic examinations were enrolled...
October 5, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
keyword
keyword
74071
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"